Global Intravenous Solutions Market Size, Share & Trends Analysis Report by Product (TPN, PPN), by Nutrients (Vitamins & Minerals, Single-dose Amino Acids), and by Region (EU, APAC, North America), Segment Forecasts, 2022-2030

The global intravenous solutions market size is expected to reach USD 22.01 billion by 2030, registering a CAGR of 8.0% The growing incidence rate of chronic diseases such as cancer, increase in the number of premature births, and shortage of I.V. solutions in the U.S. are some of the key factors expected to drive the market.

One of the prime areas wherein intravenous (IV) fluids find usage is severe dehydration. Severe dehydration is seen in diseases such as diarrhea, resulting in the depletion of fluids from the body. According to the WHO, in 2017, diarrhea was the second leading cause of death in children under 5 years of age with around 5,25,000 lives lost each year. Intravenous (IV) fluids can play a key role in the treatment and prevention of deaths caused due to dehydration/fluid loss associated with diarrhea. Other cases where intravenous fluids find application include surgeries and emergencies.

The ongoing COVID-19 pandemic is expected to have a positive impact on the market. Intensive Care Units (ICU) worldwide are either operating at full capacity or are overcrowded due to the high influx of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As per an article published by BBC, in January 2021, critical care wards across England were running at full capacity. Nutritional care is one of the essential elements in managing these patients. This has increased the demand for intravenous (IV) fluids, as many of the patients, especially the elderly population are placed on ventilators and are unable to consume food orally.

Intravenous Solutions Market Report Highlights

The Total Parenteral Nutrition (TPN) segment led the segment in terms of revenue share in 2020 owing to its growing applications in the management of chronic diseases.
The increasing number of surgeries and post-operative nutritional management is a prime factor driving the vitamins and minerals (salt and electrolyte) segment’s growth.
North America dominated the market with a revenue share of nearly 40.8% in 2020 due to the high usage of IV fluids in the U.S..

This product will be delivered within 1-3 business days.

Frequently Asked Questions about the Global Intravenous Solutions Market

What is the estimated value of the Global Intravenous Solutions Market?

The Global Intravenous Solutions Market was estimated to be valued at $11.92 Billion in 2022.

What is the growth rate of the Global Intravenous Solutions Market?

The growth rate of the Global Intravenous Solutions Market is 8.0%, with an estimated value of $22.01 Billion by 2030.

What is the forecasted size of the Global Intravenous Solutions Market?

The Global Intravenous Solutions Market is estimated to be worth $22.01 Billion by 2030.

Who are the key companies in the Global Intravenous Solutions Market?

Key companies in the Global Intravenous Solutions Market include Fresenius Kabi AG, Pfizer inc., Otsuka Pharmaceutical Co., Ltd., Baxter, b. braun melsungen ag, Vifor Pharma Management Ltd., JW Life Science, Amanta Healthcare, ICU MEDICAL and Grifols, S.A..

Report Attribute	Details
No. of Pages	98
Published	June 2022
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 11.92 Billion
Forecasted Market Value ( USD ) by 2030	$ 22.01 Billion
Compound Annual Growth Rate	8.0%
Regions Covered	Global
No. of Companies Mentioned	10

Chapter 1 Methodology and Scope

1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Nutrients
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective-1:
1.10.2 Objective-2:
1.10.3 Objective-3:
1.10.4 Objective-4:

Chapter 2 Executive Summary

2.1 Market Snapshot

Chapter 3 Intravenous Solutions Market: Variables, Trends & Scope

3.1 Market Segmentation & Scope
3.2 Market Variable Analysis
3.2.1 Market Driver Analysis
3.2.1.1 Increasing natality
3.2.1.2 Risk of malnutrition
3.2.1.3 Rising geriatric population
3.2.1.4 Increasing incidence of cancer
3.2.2 Market Restraint Analysis
3.2.2.1 Shortage of parenteral nutrition products
3.2.2.2 Increased use of enteral nutrition
3.2.2.3 High risk of infection
3.2.2.4 Stringent regulations
3.3 Penetration & Growth Prospect Mapping
3.4 Intravenous Solutions Market: Analysis Tools
3.4.1 Pestel Analysis
3.4.2 Porter’s Five Forces Analysis
3.5 COVID-19 Impact on Intravenous Solutions Market

Chapter 4 Intravenous Solutions Market: Product Segment Analysis

4.1 Intravenous Solutions: Market Share Analysis, 2021 & 2030
4.2 Total Parenteral Nutrition (TPN)
4.2.1 Total Parenteral Nutrition (TPN) market, 2018-2030 (USD Million)
4.3 Peripheral Parenteral Nutrition (PPN)
4.3.1 Peripheral Parenteral Nutrition (PPN) market, 2018-2030 (USD Million)

Chapter 5 Intravenous Solutions Market: Nutrients Segment Analysis

5.1 Intravenous Solutions: Market Share Analysis, 2021 & 2030
5.2 Carbohydrates
5.2.1 Carbohydrates market, 2018-2030 (USD Million)
5.3 Single Dose Amino Acids
5.3.1 Single dose amino acids market, 2018-2030 (USD Million)
5.4 Vitamins and Minerals
5.4.1 Vitamins and minerals market, 2018-2030 (USD Million)
5.5 Parenteral Lipid Emulsion
5.5.1 Parenteral lipid emulsion market, 2018-2030 (USD Million)
5.6 Others
5.6.1 Others market, 2018-2030 (USD Million)

Chapter 6 Intravenous Solutions Market: Regional Analysis

6.1 Intravenous Solutions: Market Share Analysis, 2021 & 2030
6.2 North America
6.2.1 North America Intravenous Solutions market, 2018-2030 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Intravenous Solutions market, 2018-2030 (USD Million)
6.2.3 Canada
6.2.3.1 Canada intravenous solutions market, 2018-2030 (USD Million)
6.3 Europe
6.3.1 Europe intravenous solutions market, 2018-2030 (USD Million)
6.3.2 U.K.
6.3.2.1 U.K. intravenous solutions market, 2018-2030 (USD Million)
6.3.3 Germany
6.3.3.1 Germany intravenous solutions market, 2018-2030 (USD Million)
6.3.4 France
6.3.4.1 France intravenous solutions market, 2018-2030 (USD Million)
6.3.5 Russia
6.3.5.1 Russia intravenous solutions market, 2018-2030 (USD Million)
6.3.6 Switzerland
6.3.6.1 Switzerland intravenous solutions market, 2018-2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific intravenous solutions market, 2018-2030 (USD Million)
6.4.2 Japan
6.4.2.1 Japan intravenous solutions market, 2018-2030 (USD Million)
6.4.3 China
6.4.3.1 China intravenous solutions market, 2018-2030 (USD Million)
6.4.4 India
6.4.4.1 India intravenous solutions market, 2018-2030 (USD Million)
6.4.5 Australia
6.4.5.1 Australia intravenous solutions market, 2018-2030 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea intravenous solutions market, 2018-2030 (USD Million)
6.5 Latin America
6.5.1 Latin America intravenous solutions market, 2018-2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil intravenous solutions market, 2018-2030 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico intravenous solutions market, 2018-2030 (USD Million)
6.6 MEA
6.6.1 MEA intravenous solutions market, 2018-2030 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa intravenous solutions market, 2018-2030 (USD Million)

Chapter 7 Company Profiles

7.1 Company Profiles
7.1.1 Fresenius Kabi AG
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.2 Pfizer inc.
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.3 Otsuka Pharmaceutical Co., Ltd.
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product benchmarking
7.1.4 Baxter
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 b. braun melsungen ag
7.1.5.1 Company overview
7.1.5.2 Financial performance
7.1.5.3 Product benchmarking
7.1.5.4 Strategic initiatives
7.1.6 Vifor Pharma Management Ltd.
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Product benchmarking
7.1.7 JW Life Science
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.8 Amanta Healthcare
7.1.8.1 Company overview
7.1.8.2 Product benchmarking
7.1.9 ICU MEDICAL
7.1.9.1 Company overview
7.1.9.2 Financial performance
7.1.9.3 Product benchmarking
7.1.9.4 Strategic initiatives
7.1.10 Grifols, S.A.
7.1.10.1 Company overview
7.1.10.2 Financial performance
7.1.10.3 Product benchmarking

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 State-wise premature birth rate for the U.S. (2021)
Table 4 List of essential and nonessential amino acids
Table 5 Composition of amino acid injection
Table 6 Physiological importance of polyunsaturated fatty acids

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity Flow Analysis
Fig. 9 Volume Price Analysis
Fig. 10 Intravenous solutions market snapshot (2021)
Fig. 11 Market trends and outlook
Fig. 12 Intravenous solutions market segmentation
Fig. 13 Market driver relevance analysis (Current & future impact)
Fig. 14 Number of undernourished people in the world, 2018-2030 (Million and Percentage)
Fig. 15 Global geriatric population, 2018-2030 (Million)
Fig. 16 North America geriatric population (Over 60 Years) (Million) (2018-2030)
Fig. 17 Market restraint relevance analysis (Current & future impact)
Fig. 18 Penetration & growth prospect mapping
Fig. 19 SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 20 PORTER’S ANALYSIS
Fig. 21 Intravenous solutions market product type outlook: Segment dashboard
Fig. 22 Intravenous solutions market: Product type movement analysis
Fig. 23 Total parenteral nutrition (TPN) market, 2018-2030 (USD Million)
Fig. 24 Peripheral parenteral nutrition (PPN) market, 2018-2030 (USD Million)
Fig. 25 Intravenous solutions market nutrient type outlook: Segment dashboard
Fig. 26 Intravenous solutions market: Nutrient type movement analysis
Fig. 27 Carbohydrates market, 2018-2030 (USD Million)
Fig. 28 Single dose amino acids market, 2018-2030 (USD Million)
Fig. 29 Vitamins and minerals market, 2018-2030 (USD Million)
Fig. 30 Parenteral lipid emulsion market, 2018-2030 (USD Million)
Fig. 31 Others market, 2018-2030 (USD Million)
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 Regional outlook, 2021 & 2030
Fig. 34 North America market, 2018-2030 (USD Million)
Fig. 35 U.S. market, 2018-2030 (USD Million)
Fig. 36 Canada market, 2018-2030 (USD Million)
Fig. 37 Europe market, 2018-2030 (USD Million)
Fig. 38 U.K. market, 2018-2030 (USD Million)
Fig. 39 Germany market, 2018-2030 (USD Million)
Fig. 40 France market, 2018-2030 (USD Million)
Fig. 41 Russia market, 2018-2030 (USD Million)
Fig. 42 Switzerland market, 2018-2030 (USD Million)
Fig. 43 Asia Pacific market, 2018-2030 (USD Million)
Fig. 44 Japan market, 2018-2030 (USD Million)
Fig. 45 China market, 2018-2030 (USD Million)
Fig. 46 India market, 2018-2030 (USD Million)
Fig. 47 Australia market, 2018-2030 (USD Million)
Fig. 48 South Korea market, 2018-2030 (USD Million)
Fig. 49 Latin America market, 2018-2030 (USD Million)
Fig. 50 Brazil market, 2018-2030 (USD Million)
Fig. 51 Mexico market, 2018-2030 (USD Million)
Fig. 52 MEA market, 2018-2030 (USD Million)
Fig. 53 South Africa market, 2018-2030 (USD Million)